Are there any clinical trials studying lurbinectedin's impact on fetuses?

Short answer: There aren’t any publicly listed clinical trials specifically designed to study lurbinectedin’s effects on fetuses.

What this typically means:
- Clinical trials for cytotoxic cancer drugs rarely enroll pregnant people, so dedicated fetal/toxicity studies in humans aren’t expected.
- The approved labeling for lurbinectedin (Zepzelca) notes that there are no adequate data in pregnant women and warns of potential fetal harm based on animal studies. It emphasizes contraception for people of reproductive potential and avoiding pregnancy during treatment.
- Preclinical data in animals suggest embryo/fetal risks, but human fetal outcome data come mainly from case reports or post-marketing surveillance, not prospective fetal studies.

If you want to check for any trials yourself, you can search ClinicalTrials.gov for terms like “lurbinectedin pregnancy,” “lurbinectedin fetal,” or “embryo-fetal development.” If you’d like, tell me your region and I can help look up current listings or provide the exact labeling references. And as always, for patient-specific concerns, discuss with a healthcare professional.